|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
19,990,000 |
Market
Cap: |
3.10(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.155 - $0.155 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Synthetic Biologics is a clinical-stage company developing therapeutics designed to prevent and treat gastrointestinal (GI) diseases. Co.'s main clinical development candidates are: SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the GI tract to prevent microbiome damage, Clostridioides difficile infection, overgrowth of pathogenic organisms, the emergence of antimicrobial resistance and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase intended to treat both local GI and systemic diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
240,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$159,974 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
7 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kanzer Steve H |
CEO |
|
2006-11-02 |
4 |
B |
$0.67 |
$4,747,874 |
I/I |
7,086,379 |
7,086,379 |
2.64 |
- |
|
Bisgaier Charles Phd |
President |
|
2006-11-02 |
4 |
A |
$2.02 |
$200,190 |
I/I |
99,104 |
99,104 |
|
- |
|
Manion Michael F |
President |
|
2006-11-01 |
4 |
D |
$0.27 |
$655,101 |
D/D |
(2,426,300) |
340,000 |
|
- |
|
Kanzer Steve H |
Chief Executive Officer |
|
2006-10-31 |
4 |
B |
$0.00 |
$0 |
I/I |
7,086,380 |
7,086,380 |
2.58 |
- |
|
Kanzer Steve H |
CEO |
|
2006-10-31 |
4 |
B |
$0.00 |
$0 |
I/I |
7,086,379 |
7,086,379 |
2.56 |
- |
|
Kanzer Steve H |
CEO |
|
2006-10-31 |
4/A |
B |
$0.00 |
$0 |
I/I |
7,086,379 |
7,086,379 |
2.56 |
- |
|
Bisgaier Charles Phd |
Director |
|
2006-10-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
297,309 |
|
- |
|
Stergis Nicholas |
Director |
|
2006-10-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,065,876 |
|
- |
|
Kanzer Steve H |
CEOOfficer |
|
2006-10-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
21,259,138 |
|
- |
|
Manion Michael F |
PRES CEO |
|
2006-06-30 |
4 |
A |
$0.01 |
$4,363 |
D/D |
436,300 |
2,766,300 |
|
- |
|
Manion Michael F |
President |
|
2006-05-31 |
4 |
B |
$0.01 |
$9,350 |
D/D |
935,000 |
2,330,000 |
3.15 |
- |
|
Manion Michael F |
PRESIDENT |
|
2005-09-30 |
4 |
B |
$0.01 |
$11,150 |
D/D |
1,115,000 |
1,395,000 |
3.15 |
- |
|
Manion Michael F |
PresidentOfficer |
|
2005-07-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
70,000,000 |
|
- |
|
63 Records found
|
|
Page 3 of 3 |
|
|